S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NYSE:CANF

Can-Fite BioPharma (CANF) Stock Price, News & Analysis

$2.22
-0.04 (-1.77%)
(As of 03/28/2024 ET)
Today's Range
$2.22
$2.30
50-Day Range
$1.93
$2.26
52-Week Range
$1.52
$3.33
Volume
7,246 shs
Average Volume
14,412 shs
Market Capitalization
$7.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Can-Fite BioPharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
575.7% Upside
$15.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Can-Fite BioPharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.85) to ($0.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.78 out of 5 stars

CANF stock logo

About Can-Fite BioPharma Stock (NYSE:CANF)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CANF Stock Price History

CANF Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Historical Prices
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Can-Fite BioPharma Ltd. (CANF)
Can Fite Biopharma Ltd (CANF)
Can Fite Biopharma Ltd ADR (CANF)
See More Headlines
Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/30/2021
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$18.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+575.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,170,000.00
Net Margins
-1,146.62%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$785,000.00
Book Value
$1.33 per share

Miscellaneous

Free Float
3,512,000
Market Cap
$7.86 million
Optionable
Not Optionable
Beta
1.52
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Pnina Fishman Ph.D. (Age 76)
    Founder, Chief Scientific Officer & Executive Chairperson
    Comp: $644k
  • Mr. Motti Farbstein (Age 60)
    CEO & Chief Operating and Financial Officer
    Comp: $414k
  • Dr. Sari Fishman Ph.D. (Age 52)
    Vice President of Business Development
    Comp: $325k
  • Dr. Ilan Cohn Ph.D. (Age 70)
    Co-Founder & Director
  • Dr. Stephen A. Harrison FACP
    M.D., Member of Clinical Advisory Board & Consulting Chief Medical Officer

CANF Stock Analysis - Frequently Asked Questions

Should I buy or sell Can-Fite BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CANF shares.
View CANF analyst ratings
or view top-rated stocks.

What is Can-Fite BioPharma's stock price target for 2024?

1 analysts have issued 12 month price objectives for Can-Fite BioPharma's shares. Their CANF share price targets range from $12.00 to $18.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 575.7% from the stock's current price.
View analysts price targets for CANF
or view top-rated stocks among Wall Street analysts.

How have CANF shares performed in 2024?

Can-Fite BioPharma's stock was trading at $2.20 on January 1st, 2024. Since then, CANF stock has increased by 0.9% and is now trading at $2.22.
View the best growth stocks for 2024 here
.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) issued its earnings results on Tuesday, November, 30th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $1.00. The company earned $0.25 million during the quarter. Can-Fite BioPharma had a negative net margin of 1,146.62% and a negative trailing twelve-month return on equity of 143.59%.

When did Can-Fite BioPharma's stock split?

Can-Fite BioPharma shares reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Can-Fite BioPharma's major shareholders?

Can-Fite BioPharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.36%) and Schechter Investment Advisors LLC (0.57%).

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CANF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners